A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.

Evaluation of XTYW007 in Healthy Subjects and Healthy Subjects With Elevated LDL-C:A Randomized, Double-Blind, Single-Center Phase I/IIa Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect Following Single and Multiple Doses

Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.

Study Overview

• Status: Not yet recruiting
• Conditions: Non-Alcoholic Fatty Liver Disease
• Intervention / Treatment: Drug: Test drug XTYW007 capsules and placebo,Single dose group; Drug: Test drug XTYW007 capsules and placebo,Food Impact Group; Drug: Test drug XTYW007 capsules and placebo,Multiple dosing group

Detailed Description

This study is a single-center, randomized, double-blind Phase I/IIa clinical trial assessing the safety, tolerability, and pharmacokinetics of single and multiple doses.Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.

• Study Type: Interventional
• Enrollment (Estimated): 94
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• China
  • Changchun
    • Jilin, Changchun, China
      • The First Hospital of Jilin University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Subjects voluntarily sign the informed consent before the trial, and fully understand the content, process and possible adverse effects of the trial;
2. They are able to complete the study according to the requirements of the trial protocol;
3. Subjects (including partners) are willing to have no pregnancy plan and voluntarily use effective contraceptive measures within 6 months from screening to the last dose of study drug;
4. Male and female subjects between the ages of 18 and 65 (including borderline values);
5. Male subjects weighing not less than 50 kg and female subjects weighing not less than 45 kg. Body mass index (BMI) = weight (kg)/ height 2 (m2), BMI within the range of 18-28 kg/m2 (including the threshold value);
6. During screening, for single-dose studies, fasting low-density lipoprotein cholesterol (LDL-C): 80 mg/dL < LDL-C < 120 mg/dL (2.06 mmol/L ~ 3.1 mmol/L); for multiple-dose studies, fasting low-density lipoprotein cholesterol (LDL-C) > 110 mg/dL (2.85 mmol/L);
7. Physical examination and vital signs are normal or abnormal without clinical significance.

Exclusion Criteria:

1. Individuals with allergic constitution (allergic to multiple drugs and foods) or intolerance to β-blockers;
2. History of thyroid-related diseases and/or thyroid function abnormalities during the screening phase that are clinically significant;
3. Individuals who smoked more than 5 cigarettes per day in the 3 months prior to the trial;
4. History of drug abuse and/or alcoholism (consuming 14 units of alcohol per week: 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine);
5. Blood donation or significant blood loss (>450 mL) within 3 months prior to taking the study drug;
6. Use of any prescription drugs, over-the-counter drugs, vitamins, herbal products, or alcohol within 14 days before taking the study drug;
7. Consumption of special foods (such as grapefruit, mango, dragon fruit, grape juice, orange juice, etc., rich in flavonoids or coumarins) within 2 weeks before taking the study drug, or engaging in intense exercise, or other factors affecting drug absorption, distribution, metabolism, or excretion;
8. Significant changes in diet or exercise habits recently;
9. Use of the study drug or participation in a drug clinical trial within 3 months before taking the study drug;
10. Difficulty swallowing or any gastrointestinal diseases affecting drug absorption within 6 months prior to the study;
11. Any disease that increases bleeding risk, such as hemorrhoids, acute gastritis, or gastroduodenal ulcer;
12. Clinically significant ECG abnormalities; QTcF > 470 ms (QTcF = QT/(RR)^0.33);
13. Female subjects who are breastfeeding during the screening or trial phase, planning pregnancy in the near future, or have positive serum pregnancy results;
14. Abnormal clinical laboratory test results with clinical significance, or other clinical findings within 12 months prior to screening that are clinically significant, including but not limited to diseases of the gastrointestinal tract, kidney, liver, nervous system, hematopoietic system, endocrine system, tumors, lungs, immune system, mental health, or cardiovascular and cerebrovascular systems;
15. Any positive result for hepatitis B surface antigen, hepatitis C antibody/core antigen, HIV antigen/antibody, or syphilis treponema antibody during screening;
16. Occurrence of acute illness or concomitant medication use from the screening phase to the start of study medication;
17. Consumption of chocolate, any caffeine-containing or xanthine-containing foods or beverages within 24 hours before taking the study drug;
18. Serum creatinine clearance ≤ 70 mL/min [calculation formula: Ccr: (140 - age) × weight (kg) / (0.818 × Scr) (μmol/L), ×0.85 for females];
19. Subjects with special dietary requirements who cannot consume the complete study meal or who do not agree to adhere to water intake regimen and position restrictions during the trial;
20. Subjects whom the investigator considers to have other factors that make them unsuitable for participation in this trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single dose group; Group 1 (0.2 mg), Group 2 (0.6 mg), Group 3 (1.5 mg), Group 4 (3 mg), Group 5, Group A (6 mg), Group 6 (10 mg), Group 7 (15 mg), optional dose Group 8 (20 mg)	Drug: Test drug XTYW007 capsules and placebo,Single dose group; Each group consists of 8 people, with 6 receiving the trial drug XTYW007 and 2 receiving a placebo. The sentinel method is used for enrollment, meaning that the first 2 subjects (one male and one female, both receiving the trial drug) are enrolled and observed for 96 hours (after the Day 5 tolerance assessment). If there are no intolerable reactions, the remaining 6 subjects are enrolled and randomly assigned to receive the trial drug or placebo in a 2:1 ratio.
Experimental: Food Impact Group; Group 5, Subgroup A（6mg）, Group 5, Subgroup B（ 6 mg）	Drug: Test drug XTYW007 capsules and placebo,Food Impact Group; A two-period crossover administration was used, with a 14-day washout period. In Group A, 8 subjects received the drug on D1 under fasting conditions in the first period, and on D15 under fed conditions in the second period. In Group B, 6 subjects taking the investigational drug received it on D1 under fed conditions in the first period, and on D15 under fasting conditions in the second period.
Experimental: Multiple dosing group; Group 9 (1.5 mg), Group 10 (6 mg), Group 11 (15 mg)	Drug: Test drug XTYW007 capsules and placebo,Multiple dosing group; Each group consists of 8 subjects, with 6 receiving the investigational drug XTYW007 and 2 receiving a placebo. A sentinel dosing approach is used, where 2 subjects (one male and one female) are first enrolled and administered the investigational drug. After 96 hours of observation (tolerance evaluation on Day 5), if no intolerable issues occur, the remaining 6 subjects are enrolled and randomized 2:1 to receive the investigational drug or placebo. In the multiple-dose group, the drug is administered once every morning on an empty stomach (QD) for 14 consecutive days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-related adverse events	Number of participants who experienced treatment-related adverse events as assessed by CTCAE v5.0.	Days 1-11 of administration
Cmax	Cmax	Days 1-11 of administration
Tmax	Tmax	Days 1-11 of administration
t1/2	t1/2	Days 1-11 of administration
AUC	AUC	Days 1-11 of administration
CL/F	CL/F	Days 1-11 of administration
Vz/F	Vz/F	Days 1-11 of administration
CLr/F	CLr/F	Days 1-11 of administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ae0-72 h	Ae0-72 h	Days 1-4 of administration
Fe0-72 h	Fe0-72 h	Days 1-4 of administration
Blood lipids	TC , TG , LDL-C, HDL-C, Apo A1, Apo B, Lp(a)	Days 1-11 of administration
Thyroid function	TSH, TT4, TT3, FT4, FT3	Days 1-11 of administration
Sex hormone-binding globulin (SHBG)	SHBG	Days 1-11 of administration

Collaborators and Investigators

• Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): March 25, 2026
• Primary Completion (Estimated): February 26, 2027
• Study Completion (Estimated): May 27, 2027

Study Registration Dates

• First Submitted: February 3, 2026
• First Submitted That Met QC Criteria: February 9, 2026
• First Posted (Actual): February 12, 2026

Study Record Updates

• Last Update Posted (Actual): February 12, 2026
• Last Update Submitted That Met QC Criteria: February 9, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease; Population Characteristics; Demography; Population Groups
• Other Study ID Numbers: XTYW007-2025-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No